Nadalin, S., Zatković, L., Peitl, V., Karlović, D., Vilibić, M., Silić, A. ... Buretić Tomljanović, A. (2024). An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment. Prostaglandins, Leukotrienes and Essential Fatty Acids, 200.. doi: 10.1016/j.plefa.2023.102604
Nadalin, Sergej, et al. "An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment." Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 200, 2024. https://doi.org/10.1016/j.plefa.2023.102604
Nadalin, Sergej, Lena Zatković, Vjekoslav Peitl, Dalibor Karlović, Maja Vilibić, Ante Silić, Sanja Dević Pavlić and Alena Buretić Tomljanović. "An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment." Prostaglandins, Leukotrienes and Essential Fatty Acids 200 (2024). https://doi.org/10.1016/j.plefa.2023.102604
Nadalin, S., et al. (2024) 'An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment', Prostaglandins, Leukotrienes and Essential Fatty Acids, 200. doi: 10.1016/j.plefa.2023.102604
Nadalin S, Zatković L, Peitl V, Karlović D, Vilibić M, Silić A, and sur.. An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment. Prostaglandins, Leukotrienes and Essential Fatty Acids [Internet]. 2024 January [cited 2024 August 19];200. doi: 10.1016/j.plefa.2023.102604
S. Nadalin, et al., "An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment", Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 200, January 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:091129. [Accessed: 19 August 2024]